InflaRx (IFRX) Research & Development (2016 - 2026)
InflaRx's (IFRX) quarterly Research & Development came in at -$4.9 million in Q1 2026, up 33.84% year-on-year from -$3.6 million in Q1 2025, and down 109.08% quarter-over-quarter from $53.8 million in Q4 2025.
InflaRx (IFRX) Research & Development (2016 - 2026) Analysis & Trends
InflaRx has disclosed Research & Development across 11 years of filings, most recently posting -$4.9 million for Q1 2026.
- Research & Development for Q1 2026 came in at -$4.9 million, up 33.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.4 million (up 331951.13% YoY), and the FY2025 annual result was $29.9 million, up 3569097.07% from the prior year.
- Research & Development came in at -$4.9 million for Q1 2026 at InflaRx, down from $53.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $53.8 million in Q4 2025 to a low of -$15812.4 billion in Q1 2023.
- The 5-year median for Research & Development is -$8.0 million (2023), against an average of -$1377.2 billion.
- Peak annual rise in Research & Development reached 516.96% in 2023, while the deepest fall reached 134538545.21% in 2023.
- InflaRx's Research & Development stood at -$8.5 million in 2022, then surged by 516.96% to $35.5 million in 2023, then decreased by 14.24% to $30.4 million in 2024, then surged by 76.76% to $53.8 million in 2025, then sank by 109.08% to -$4.9 million in 2026.
- The last three Research & Development figures came in at -$4.9 million (Q1 2026), $53.8 million (Q4 2025), and -$7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -58.00 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.88 Mn |
| Dec 31, 2025 | 53.76 Mn |
| Sep 30, 2025 | -7.30 Mn |
| Jun 30, 2025 | -8.15 Mn |
| Mar 31, 2025 | -7.38 Mn |
| Dec 31, 2024 | 30.41 Mn |
| Sep 30, 2024 | -12.23 Mn |
| Jun 30, 2024 | -10.79 Mn |
| Mar 31, 2024 | -7.93 Mn |
| Dec 31, 2023 | 35.46 Mn |
| Sep 30, 2023 | -7.95 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Mar 31, 2023 | -15,812.37 Bn |
| Dec 31, 2022 | -8.50 Mn |
| Sep 30, 2022 | -7,599.72 Bn |
| Jun 30, 2022 | 11.93 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -40,837.37 Bn |
| Sep 30, 2021 | -11.04 Mn |
| Jun 30, 2021 | 13.61 Mn |